MedTrace Logo

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

NCT04192903 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2022-04-20

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate therapeutic efficacy and safety of Chidamide combined with Cisplatin for relapsed or metastatic triple-negative breast cancer.

Conditions

  • Triple-negative Breast Cancer

Interventions

DRUG

Chidamide combined with Cisplatin

Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • xichun Hu,MD · Fudan University

  • Jian Zhang,MD · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-25
Primary Completion
2022-06-01
Completion
2022-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04192903 on ClinicalTrials.gov